- Home
- IBO vs SYBX Comparison
IBO vs SYBX Comparison
Compare IBO & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- SYBX
- Stock Information
- Founded
- IBO 2018
- SYBX N/A
- Country
- IBO United States
- SYBX United States
- Employees
- IBO N/A
- SYBX N/A
- Industry
- IBO
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- SYBX Health Care
- Exchange
- IBO NYSE
- SYBX Nasdaq
- Market Cap
- IBO 17.9M
- SYBX 16.5M
- IPO Year
- IBO 2024
- SYBX N/A
- Fundamental
- Price
- IBO $1.56
- SYBX $1.46
- Analyst Decision
- IBO
- SYBX Hold
- Analyst Count
- IBO 0
- SYBX 3
- Target Price
- IBO N/A
- SYBX $1.00
- AVG Volume (30 Days)
- IBO 31.8K
- SYBX 25.8K
- Earning Date
- IBO 02-23-2025
- SYBX 11-12-2024
- Dividend Yield
- IBO N/A
- SYBX N/A
- EPS Growth
- IBO N/A
- SYBX N/A
- EPS
- IBO 0.01
- SYBX N/A
- Revenue
- IBO N/A
- SYBX $2,777,000.00
- Revenue This Year
- IBO N/A
- SYBX N/A
- Revenue Next Year
- IBO N/A
- SYBX N/A
- P/E Ratio
- IBO $129.11
- SYBX N/A
- Revenue Growth
- IBO N/A
- SYBX 292.23
- 52 Week Low
- IBO $1.16
- SYBX $1.22
- 52 Week High
- IBO $3.25
- SYBX $3.73
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- SYBX 53.64
- Support Level
- IBO N/A
- SYBX $1.36
- Resistance Level
- IBO N/A
- SYBX $1.47
- Average True Range (ATR)
- IBO 0.00
- SYBX 0.08
- MACD
- IBO 0.00
- SYBX 0.00
- Stochastic Oscillator
- IBO 0.00
- SYBX 62.50
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.